BiologicsFinancialSports Medicine

An unmet need for knees: Biotech Histogenics sets terms for $60 million IPO

Keywords / Tickers: HSGX, XON
Related Links: Upcoming IPOs
Tags

Josh Sandberg

Josh Sandberg is the President of Ortho Sales Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close